Clinical evaluation of a new fractional ablative 2910 nm erbium laser on photodamaged skin: A pilot study.

Abstract

To examine the efficacy and safety of a new fractional, ablative erbium:glassfiber (Er:glass) laser (2910 nm) at improving clinical signs of photodamaged skin. Thirty-sevenhealthy participants aged 38-75 years with photodamaged skin were enrolled into two treatment groups. Group A (n = 14) received up to four laser treatments with mild settings, and focal facial subunits were treated with deeper settings. Group B (n = 23) received a single treatment using deeper settings. Following treatment, pain scores and severity and duration of skin responses (erythema, edema, and pinpoint bleeding) were assessed. Primary outcome was the improvement in participant and investigator Global Aesthetic Improvement Scale (GAIS) at 3-month follow-up. Secondary outcomes were participant satisfaction with treatment and whether they would repeat treatment. Thirty-fiveparticipants completed the study (n = 1 lost to follow up in each group). Both groups had similar mean participant and investigator GAIS scores of 3/5 corresponding to "Improvement." All but two patients (both from Group A) reported improvement, satisfaction with treatment, and would repeat treatment. Posttreatment skin responses were mild-to-moderate, lasting up to 5 days. There was no scarring or dyspigmentation. The 2910 nm Er:glass laser provided improvement in photoaging with high patient satisfaction.